Brian Leyland‐Jones
Author
Alternate names B R Leyland‐Jones, B LEYLANDJONES, Brian Leyland‐Jones, B. R. LEYLAND‐JONES, B. Leyland‐Jones +1 more
Institution McGill University
Past institutions McGill University, Avera Health, WIN Consortium, Worldwide Universities Network, National Foundation for Cancer Research +5 more
ORCID: Yes
H-index: 64
I10-index: 164
Works count: 443
Citations count: 30,760
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 · Dennis J. Slamon, Brian Leyland‐Jones, et al. · New England Journal of Medicine
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
2005 · Martine Piccart, Marion Procter, et al. · New England Journal of Medicine
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
2017 · David Cameron, Martine Piccart, et al. · The Lancet